13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2021220014 | 01/07/2022 | 25/06/2022 | A Clinical, Imaging and Biomarker Study in Neuromyelitis Optica Spectrum Disorder (NMOSD) with Satralizumab as an Intervention | SAKURABONSAI: CLINICAL, IMAGING AND BIOMARKER OPEN-LABEL STUDY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) WITH SATRALIZUMAB AS AN INTERVENTION | Neuromyelitis Optica Spectrum Disorder (NMOSD) | Satralizumab: 120 mg SC injection every 4 weeks (Q4W) | Regine Buffels | NULL | Pending | >= 18age old | <= 74age old | Both | 100 | Phase 4 | United States;Canada;Italy;France;Germany;India;Korea;Turkey;Japan |
| 2 | ChiCTR2200057880 | 2022-04-01 | 2022-03-20 | A prospective, self-controlled study to explore efficacy and safety of orelabrutinib in AQP4-IgG positive neuromyelitis optica spectrum disorder | A prospective, self-controlled study to explore efficacy and safety of orelabrutinib in AQP4-IgG positive neuromyelitis optica spectrum disorder | Neuromyelitis optica spectrum disorder | Case group:Orelabrutinib, orally, 50 mg QD; | Peking Union Medical College Hospital | NULL | Pending | 18 | 75 | Both | Case group:23; | Phase 1 | China |
| 3 | ChiCTR2100052936 | 2021-11-10 | 2021-11-06 | The establishment of metabolic fingerprints-aided diagnostic model of neuromyelitis optica spectrum disorder | High-throughput metabolic fingerprints characterize neuromyelitis optica spectrum disorder | Neuromyelitis Optica Spectrum Disorders | Gold Standard:Cell-based assay (CBA) for antibody testing as recommended.;Index test:Matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS) is responsible for the obtainment of biofluid metabolic fingerprints, which is further processed by machine learning algorithm, yielding Receiver Operating Characteristic (ROC) curve and area under curve (AUC) calculated to provide comparison.; | Renji Hospital, School of Medicine, Shanghai Jiao Tong University | NULL | Pending | 18 | 85 | Both | Target condition:76;Difficult condition:13 | N/A | China |
| 4 | JPRN-UMIN000043910 | 2021/06/01 | 01/06/2021 | Association between brain atrophy and intestinal permeability in patients with multiple sclerosis | Association between brain atrophy and intestinal permeability in patients with multiple sclerosis - Brain atrophy and intestinal permeability in MS | multiple sclerosis | A standard solution of lactulose (5 g) and mannitol (2 g)in 500 mL of tap water was ingested before bed. Urine was collected the following morning in a container (with 5 mL of thymol solution). | Department of Neurology and Neurological Science, Tokyo Medical and Dental University | NULL | Pending | 18years-old | 80years-old | Male and Female | 40 | Not selected | Japan |
| 5 | ChiCTR2100043013 | 2021-01-31 | 2021-02-04 | Efficacy difference between low dose rituximab and mycophenolate mofetil in preventing recurrence of NMOSD | Efficacy difference between low dose rituximab and mycophenolate mofetil in preventing recurrence of NMOSD | Neuromyelitis optica spectrum diseases | low dose rituximab group: low dose rituximab ;mycophenolate mofetil group:mycophenolate mofetil ; | Shandong University Qilu Hospital | NULL | Pending | Both | low dose rituximab group:30;mycophenolate mofetil group:30; | Phase 4 | China | ||
| 6 | ChiCTR2000034098 | 2020-07-01 | 2020-06-23 | A New Quantitative Method Used to Evaluate Cervical Spinal Cord Damage in Multiple Sclerosis: Diffusional Kurtosis Imaging Research | A New Quantitative Method Used to Evaluate Cervical Spinal Cord Damage in Multiple Sclerosis: Diffusional Kurtosis Imaging Research | Multiple Sclerosis | Gold Standard:Conventional cervical MRI;Index test:Diffusional Kurtosis Imaging; | The First Hospital of Jilin University | NULL | Pending | Both | Target condition:48;Difficult condition:0 | China | |||
| 7 | EUCTR2011-000985-36-ES (EUCTR) | 22/02/2013 | 25/01/2012 | Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex | Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex | Spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex MedDRA version: 14.1;Level: LLT;Classification code 10041416;Term: Spasticity;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: SATIVEX Product Name: sativex Product Code: N02BG10 INN or Proposed INN: pending Other descriptive name: CANNABIDIOL | JOSE MANUEL GARCIA DOMINGUEZ | NULL | Not Recruiting | Female: yes Male: yes | Spain |